Skip to main navigation Skip to search Skip to main content

Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

  • Shi-Bing Liang
  • , Yi-Fei Wang
  • , Zhen-Chao Niu
  • , Yu-Fei Li
  • , Hui-Min Zheng
  • , Jia-Ming Huan
  • , Jie Yuan
  • , Nicola Robinson
  • , Jian-Ping Liu
  • , Yun-Lun Li
  • Postdoctoral Research Station, Shandong University of Traditional Chinese Medicine
  • Cardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
  • Centre for Evidence-Based Chinese Medicine Beijing University of Chinese Medicine
  • Centre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
  • The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
  • Institute of Health and Social Care, London South Bank University
  • Shandong Engineering Laboratory of Traditional Chinese Medicine Precision Therapy for Cardiovascular Diseases, Shandong University of Traditional Chinese Medicine, Jinan, China

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)
20 Downloads (Pure)

Abstract

Background: Chronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS. Objectives: To systematically evaluate the therapeutic effects and safety of adding TXL to Western medical treatment (WM) for CCS. Methods: We searched PubMed, Cochrane Library, CNKI, VIP, and Wanfang databases up to August 2024 for randomized controlled trials (RCTs) investigating the therapeutic effects and safety of combining TXL with WM compared to WM alone for CCS. Data analyses were conducted using RevMan 5.4 software. Results: Twenty studies involving 2091 participants were identified. Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. Adding TXL to WM showed a non-significant trend toward reducing myocardial infarction [RR 0.34, 95% CI (0.05, 2.12); NNT = 41] and sudden cardiac death [RR 0.34, 95% CI (0.01, 8.28); NNT = 65]. No increase in adverse events was observed when TXL was added to WM [RR 1.02, 95% CI (0.70, 1.49); NNT = 149]. Conclusions: Our review suggests that TXL may offer additional therapeutic benefits for CCS patients and appears to be safe when combined with WM. Further investigations are warranted to confirm the potential impact of adding TXL to WM for CCS. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024499031, PROSPERO (CRD42024499031).

Original languageEnglish
Article number1499585
JournalFrontiers in Cardiovascular Medicine
Volume11
Early online date7 Jan 2025
DOIs
Publication statusE-pub ahead of print - 7 Jan 2025
Externally publishedYes

Bibliographical note

Publisher Copyright:
2025 Liang, Wang, Niu, Li, Zheng, Huan, Yuan, Robinson, Liu and Li.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Chinese herbal medicine
  • meta-analysis
  • tongxinluo
  • clinical evidence
  • systematic review
  • cardiovascular disease
  • chronic coronary syndromes

Cite this